alanine has been researched along with Cancer of Head in 12 studies
Alanine: A non-essential amino acid that occurs in high levels in its free state in plasma. It is produced from pyruvate by transamination. It is involved in sugar and acid metabolism, increases IMMUNITY, and provides energy for muscle tissue, BRAIN, and the CENTRAL NERVOUS SYSTEM.
alanine : An alpha-amino acid that consists of propionic acid bearing an amino substituent at position 2.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The aim of this study is to evaluate the relationship between the aspartate aminotransaminase (AST) and alanine aminotransaminase (ALT) ratio and local disease control in patients with head and neck squamous cell carcinomas (HNSCC) treated with radiotherapy/chemoradiotherapy." | 8.02 | The aspartate aminotransaminase/alanine aminotransaminase (De Ritis) ratio predicts sensitivity to radiotherapy in head and neck carcinoma patients. ( Avilés-Jurado, FX; León, X; Pardo, L; Quer, M; Sansa, A; Terra, X; Valero, C; Venegas, MDP, 2021) |
| "The aim of this study is to evaluate the relationship between the aspartate aminotransaminase (AST) and alanine aminotransaminase (ALT) ratio and local disease control in patients with head and neck squamous cell carcinomas (HNSCC) treated with radiotherapy/chemoradiotherapy." | 4.02 | The aspartate aminotransaminase/alanine aminotransaminase (De Ritis) ratio predicts sensitivity to radiotherapy in head and neck carcinoma patients. ( Avilés-Jurado, FX; León, X; Pardo, L; Quer, M; Sansa, A; Terra, X; Valero, C; Venegas, MDP, 2021) |
| "Head and neck cancer (HNC) is the fifth most common cancer globally." | 3.01 | Metabolomics of head and neck cancer in biofluids: an integrative systematic review. ( Appolonova, SA; Brito, A; Carta, F; Castillo-Carniglia, A; Chuchueva, N; Fahrmann, J; Fanos, V; Grapov, D; King, E; La Frano, MR; Lewis, IA; Luevano, J; Mariani, C; Moskaleva, N; Nguyen, HN; Puxeddu, R; Reshetov, I; Rios-Castillo, I; Rusetsky, Y; Shestakova, K; Swistushkin, V, 2023) |
| "In the treatment of head and neck cancer, severity of chemoradiotherapy-induced oral mucositis has been recognized as one of the key factors affecting the outcomes of the anticancer therapies." | 2.90 | The post hoc analysis comparing the severity grades of chemoradiotherapy-induced oral mucositis scored between the central and local assessors in a multicenter, randomized controlled trial of rebamipide for head and neck cancer. ( Fujii, M; Konishi, T; Nagamoto, H; Shibasaki, Y; Ueno, T; Yurikusa, T; Zenda, S, 2019) |
| " The primary endpoint was the incidence of grade ≥ 3 oral mucositis determined by clinical examination and assessed by central review according to the Common Terminology Criteria of Adverse Events version 3." | 2.84 | Efficacy and safety of rebamipide liquid for chemoradiotherapy-induced oral mucositis in patients with head and neck cancer: a multicenter, randomized, double-blind, placebo-controlled, parallel-group phase II study. ( Beppu, T; Fujii, M; Fujii, T; Fujimoto, Y; Hasegawa, Y; Hirano, S; Iwae, S; Kojima, H; Matsushima, Y; Matsuura, K; Monden, N; Naka, Y; Nishimori, H; Ogawa, T; Okami, K; Ota, I; Sasaki, K; Tahara, M; Takahashi, S; Tanaka, K; Ueda, S; Ueda, T; Yokota, T, 2017) |
| "60 Patients diagnosed with Head & Neck cancer recruited for concurrent chemo-radiotherapy were assigned in a double blind fashion into 2 groups using computer based 1:1 ratio randomization." | 2.84 | Rebamipide gargle in preventive management of chemo-radiotherapy induced oral mucositis. ( Chaitanya, B; Chhaparwal, Y; Fernandes, D; Pai, KM; Yathiraj, PH, 2017) |
| "In this study, using HNSCC cell lines, we examined the anti-cancer effects and the mechanisms of action of docosahexaenoyl ethanolamide (DHEA) and N-arachidonoyl-L-alanine (NALA), which are polyunsaturated fatty acid (PUFA)-based ethanolamides like AEA." | 1.43 | 5-lipoxygenase mediates docosahexaenoyl ethanolamide and N-arachidonoyl-L-alanine-induced reactive oxygen species production and inhibition of proliferation of head and neck squamous cell carcinoma cells. ( Hah, JH; Jeong, WJ; Oh, SM; Park, SW; Sung, MW, 2016) |
| "Chemoradiotherapy for head and neck cancer is associated with a high incidence of severe oral mucositis; an adverse, painful event." | 1.37 | [Investigation of how to prevent mucositis induced by chemoradiotherapy]. ( Hushimi, C; Inoue, T; Kamata, S; Kobayashi, M; Masubuchi, T; Miura, K; Moya, M; Tada, Y; Tajima, H; Tosaka, C, 2011) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (16.67) | 18.7374 |
| 1990's | 1 (8.33) | 18.2507 |
| 2000's | 1 (8.33) | 29.6817 |
| 2010's | 6 (50.00) | 24.3611 |
| 2020's | 2 (16.67) | 2.80 |
| Authors | Studies |
|---|---|
| Chuchueva, N | 1 |
| Carta, F | 1 |
| Nguyen, HN | 1 |
| Luevano, J | 1 |
| Lewis, IA | 1 |
| Rios-Castillo, I | 1 |
| Fanos, V | 1 |
| King, E | 1 |
| Swistushkin, V | 1 |
| Reshetov, I | 1 |
| Rusetsky, Y | 1 |
| Shestakova, K | 1 |
| Moskaleva, N | 1 |
| Mariani, C | 1 |
| Castillo-Carniglia, A | 1 |
| Grapov, D | 1 |
| Fahrmann, J | 1 |
| La Frano, MR | 1 |
| Puxeddu, R | 1 |
| Appolonova, SA | 1 |
| Brito, A | 1 |
| Sansa, A | 1 |
| Venegas, MDP | 1 |
| Valero, C | 1 |
| Pardo, L | 1 |
| Avilés-Jurado, FX | 1 |
| Terra, X | 1 |
| Quer, M | 1 |
| León, X | 1 |
| Yokota, T | 1 |
| Ogawa, T | 1 |
| Takahashi, S | 1 |
| Okami, K | 1 |
| Fujii, T | 1 |
| Tanaka, K | 1 |
| Iwae, S | 1 |
| Ota, I | 1 |
| Ueda, T | 1 |
| Monden, N | 1 |
| Matsuura, K | 1 |
| Kojima, H | 1 |
| Ueda, S | 1 |
| Sasaki, K | 1 |
| Fujimoto, Y | 1 |
| Hasegawa, Y | 1 |
| Beppu, T | 1 |
| Nishimori, H | 1 |
| Hirano, S | 1 |
| Naka, Y | 1 |
| Matsushima, Y | 1 |
| Fujii, M | 2 |
| Tahara, M | 1 |
| Chaitanya, B | 1 |
| Pai, KM | 1 |
| Yathiraj, PH | 1 |
| Fernandes, D | 1 |
| Chhaparwal, Y | 1 |
| Ueno, T | 1 |
| Zenda, S | 1 |
| Konishi, T | 1 |
| Yurikusa, T | 1 |
| Shibasaki, Y | 1 |
| Nagamoto, H | 1 |
| Park, SW | 1 |
| Hah, JH | 1 |
| Oh, SM | 1 |
| Jeong, WJ | 1 |
| Sung, MW | 1 |
| Wagner, D | 1 |
| Anton, M | 1 |
| Vorwerk, H | 1 |
| Tosaka, C | 1 |
| Tajima, H | 1 |
| Inoue, T | 1 |
| Moya, M | 1 |
| Kobayashi, M | 1 |
| Miura, K | 1 |
| Tada, Y | 1 |
| Masubuchi, T | 1 |
| Hushimi, C | 1 |
| Kamata, S | 1 |
| Quintela-Fandino, M | 1 |
| Hitt, R | 1 |
| Medina, PP | 1 |
| Gamarra, S | 1 |
| Manso, L | 1 |
| Cortes-Funes, H | 1 |
| Sanchez-Cespedes, M | 1 |
| Creagan, ET | 1 |
| Schutt, AJ | 1 |
| Ingle, JN | 1 |
| O'Fallon, JR | 1 |
| Hotate, T | 1 |
| Kubota, A | 1 |
| Meguid, MM | 1 |
| Hitch, DC | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Phase 2 Trial of Rebamipide Liquid to Determine the Effective Dose for Prevention of Chemoradiotherapy-induced Oral Mucositis in Patients With Head and Neck Cancer[NCT02085460] | Phase 2 | 94 participants (Actual) | Interventional | 2014-03-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Investigators who had undergone specific training assessed the severity of oral mucositis twice every week. To evaluate the severity of oral mucositis objectively, the clinical findings of the oral mucosa as well as functional disorders and symptomatic aspects were recorded in the Oral Mucositis Assessment Sheet by each investigator. Photographic documentation of the oral mucosa was also submitted by each investigator, 3 days before or 57 days after initiation of chemoradiotherapy, or at the time of withdrawal. The Oral Mucositis Assessment Sheets and photographic documentation were then reviewed by the Oral Mucositis Evaluation Committee to grade the severity of oral mucositis according to the CTCAE 3.0.z (NCT02085460)
Timeframe: 77 days
| Intervention | percentage of participants (Number) |
|---|---|
| 2% Rebamipide Liquid | 29.0 |
| 4% Rebamipide Liquid | 25.0 |
| Placebo | 38.7 |
Day 1 was defined as the start of chemotherapy. (NCT02085460)
Timeframe: Days 1, 8, 15, 22, 29, 36, 43, 50, 57, 64, 71, and 77
| Intervention | participants (Number) | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Day 1 | Day 8 | Day 15 | Day 22 | Day 29 | Day 36 | Day 43 | Day 50 | Day 57 | Day 64 | Day 71 | Day 77 | |
| 2% Rebamipide Liquid | 31 | 29 | 27 | 25 | 23 | 20 | 18 | 17 | 12 | 11 | 8 | 6 |
| 4% Rebamipide Liquid | 31 | 31 | 30 | 29 | 25 | 20 | 18 | 18 | 16 | 15 | 13 | 11 |
| Placebo | 31 | 30 | 29 | 23 | 23 | 19 | 16 | 15 | 13 | 11 | 8 | 8 |
1 review available for alanine and Cancer of Head
| Article | Year |
|---|---|
Metabolomics of head and neck cancer in biofluids: an integrative systematic review.
Topics: Alanine; Body Fluids; Glucose; Head and Neck Neoplasms; Humans; Metabolomics | 2023 |
3 trials available for alanine and Cancer of Head
8 other studies available for alanine and Cancer of Head
| Article | Year |
|---|---|
The aspartate aminotransaminase/alanine aminotransaminase (De Ritis) ratio predicts sensitivity to radiotherapy in head and neck carcinoma patients.
Topics: Alanine; Alanine Transaminase; Aspartate Aminotransferases; Aspartic Acid; Biomarkers, Tumor; Carcin | 2021 |
5-lipoxygenase mediates docosahexaenoyl ethanolamide and N-arachidonoyl-L-alanine-induced reactive oxygen species production and inhibition of proliferation of head and neck squamous cell carcinoma cells.
Topics: Alanine; Antineoplastic Agents; Apoptosis; Arachidonate 5-Lipoxygenase; Arachidonic Acids; Azoles; B | 2016 |
Dose uncertainty in radiotherapy of patients with head and neck cancer measured by in vivo ESR/alanine dosimetry using a mouthpiece.
Topics: Alanine; Electron Spin Resonance Spectroscopy; Head and Neck Neoplasms; Humans; Mouth; Radiation Dos | 2011 |
[Investigation of how to prevent mucositis induced by chemoradiotherapy].
Topics: Alanine; Antineoplastic Agents; Combined Modality Therapy; Female; Head and Neck Neoplasms; Humans; | 2011 |
DNA-repair gene polymorphisms predict favorable clinical outcome among patients with advanced squamous cell carcinoma of the head and neck treated with cisplatin-based induction chemotherapy.
Topics: Adult; Aged; Aged, 80 and over; Alanine; Antineoplastic Combined Chemotherapy Protocols; Arginine; A | 2006 |
Phase II clinical trial of L-alanosine in advanced upper aerodigestive cancer.
Topics: Alanine; Carcinoma, Squamous Cell; Drug Evaluation; Female; Head and Neck Neoplasms; Humans; Leukope | 1983 |
[Studies on urinary biochemical markers in patients with head and neck cancer: especially on polyamines, beta-aminoisobutyric acid and beta-alanine (author's transl)].
Topics: Adenocarcinoma; Alanine; Aminoisobutyric Acids; beta-Alanine; Carcinoma, Squamous Cell; Head and Nec | 1981 |
Amino acid profiles correlate diagnostically with organ site in three kinds of malignant tumors.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Alanine; Amino Acids; Arginine; Breast Neoplasms; Ca | 1992 |